Technetium tc-99m depreotide is a Radioactive Diagnostic Agent. The mechanism of action of technetium tc-99m depreotide is as a Radiopharmaceutical Activity.
CAT No: 10-101-337
CAS No:174900-52-8
Chemical Name:(2S)-6-amino-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-3-[[2-[2-[(2S,5S,8S,11R,14S,17S)-14-(4-aminobutyl)-5-benzyl-8-[(4-hydroxyphenyl)methyl]-11-(1H-indol-3-ylmethyl)-4-methyl-3,6,9,12,15,18-hexaoxo-17-propan-2-yl-1,4,7,10,13,16-hexazacyclooctadec-2-yl]ethylsulfanyl]acetyl]amino]propanoyl]amino]hexanoyl]amino]-3-sulfanylpropanoyl]amino]hexanamide;technetium
Technetium TC-99M depreotide is a radiolabeled peptide compound designed for research applications involving the visualization and study of somatostatin receptor-expressing tissues. As a synthetic somatostatin analog conjugated with the gamma-emitting radioisotope technetium-99m, it combines the receptor-binding specificity of depreotide with the imaging capabilities of nuclear medicine tracers. This dual functionality enables researchers to investigate molecular recognition events, receptor expression patterns, and peptide pharmacokinetics in preclinical models. The compound's unique properties make it a valuable tool for studies centered on peptide-receptor interactions and radiopharmaceutical development.
Receptor binding studies: Technetium TC-99M depreotide is widely utilized in receptor binding assays to characterize somatostatin receptor subtypes and their distribution in various tissues. By leveraging its high affinity for somatostatin receptor subtypes, particularly SSTR2, SSTR3, and SSTR5, researchers can quantify receptor density, assess receptor occupancy, and evaluate binding kinetics in cell lines or tissue samples. These studies are fundamental for understanding receptor-mediated signaling pathways and for mapping receptor expression in different biological contexts.
Radiopharmaceutical development: The compound serves as a model system for the development and optimization of novel peptide-based radiopharmaceuticals. Its structure, which incorporates a chelated technetium-99m label, allows for the evaluation of radiolabeling strategies, stability under physiological conditions, and in vivo biodistribution profiles. Investigators can use it to compare different chelation chemistries, assess peptide modifications, and optimize pharmacokinetic properties, thereby advancing the design of next-generation targeted imaging agents.
In vivo imaging research: Technetium TC-99M depreotide is extensively used in preclinical imaging studies employing single-photon emission computed tomography (SPECT). Its selective uptake in somatostatin receptor-positive tissues enables visualization and quantification of receptor expression in animal models. Such imaging studies provide insights into tumor biology, receptor heterogeneity, and peptide tracer dynamics, supporting the validation of new imaging protocols and the evaluation of disease models in a controlled research setting.
Pharmacokinetic and biodistribution analysis: Researchers employ this radiolabeled peptide to investigate the pharmacokinetics, tissue distribution, and clearance mechanisms of peptide-based imaging agents. By tracking the gamma emissions from technetium-99m, it is possible to obtain quantitative data on tissue uptake, retention times, and metabolic stability in vivo. These analyses are critical for understanding the behavior of peptide tracers and for guiding the rational design of radiolabeled probes with improved specificity and reduced off-target accumulation.
Peptide-receptor interaction modeling: The compound provides a robust platform for studying the molecular interactions between somatostatin analogs and their cognate receptors. Using in vitro and in vivo systems, researchers can elucidate binding affinities, receptor activation profiles, and the influence of peptide structure on receptor selectivity. Such studies contribute to the broader understanding of peptide ligand-receptor dynamics and inform the development of targeted agents for molecular imaging and other research applications.
3. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
4. Cationic cell-penetrating peptides are potent furin inhibitors
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More